Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study.
Standard
Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study. / Siegerink, Bob; Maas, Renke; Vossen, Carla Y; Schwedhelm, Edzard; Koenig, Wolfgang; Böger, Rainer; Rothenbacher, Dietrich; Brenner, Hermann; Breitling, Lutz P.
in: CLIN RES CARDIOL, Jahrgang 102, Nr. 3, 3, 2013, S. 193-202.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Asymmetric and symmetric dimethylarginine and risk of secondary cardiovascular disease events and mortality in patients with stable coronary heart disease: the KAROLA follow-up study.
AU - Siegerink, Bob
AU - Maas, Renke
AU - Vossen, Carla Y
AU - Schwedhelm, Edzard
AU - Koenig, Wolfgang
AU - Böger, Rainer
AU - Rothenbacher, Dietrich
AU - Brenner, Hermann
AU - Breitling, Lutz P
PY - 2013
Y1 - 2013
N2 - Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide synthase inhibitor, which has been associated with total and cardiovascular mortality in various clinical settings. Studies on its structural isomer, symmetric dimethylarginine (SDMA), are scarce. This study aimed to determine the associations of both ADMA and SDMA levels with secondary cardiovascular disease events and all-cause mortality in patients with stable coronary heart disease (CHD).
AB - Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide synthase inhibitor, which has been associated with total and cardiovascular mortality in various clinical settings. Studies on its structural isomer, symmetric dimethylarginine (SDMA), are scarce. This study aimed to determine the associations of both ADMA and SDMA levels with secondary cardiovascular disease events and all-cause mortality in patients with stable coronary heart disease (CHD).
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Risk Factors
KW - Multivariate Analysis
KW - Prospective Studies
KW - Predictive Value of Tests
KW - Prognosis
KW - Risk Assessment
KW - Follow-Up Studies
KW - Time Factors
KW - Proportional Hazards Models
KW - Cause of Death
KW - Recurrence
KW - Kaplan-Meier Estimate
KW - Chromatography, Liquid
KW - Tandem Mass Spectrometry
KW - Germany/epidemiology
KW - Arginine/analogs & derivatives/blood
KW - Biological Markers/blood
KW - Coronary Disease/blood/diagnosis/mortality
KW - Humans
KW - Male
KW - Aged
KW - Female
KW - Middle Aged
KW - Risk Factors
KW - Multivariate Analysis
KW - Prospective Studies
KW - Predictive Value of Tests
KW - Prognosis
KW - Risk Assessment
KW - Follow-Up Studies
KW - Time Factors
KW - Proportional Hazards Models
KW - Cause of Death
KW - Recurrence
KW - Kaplan-Meier Estimate
KW - Chromatography, Liquid
KW - Tandem Mass Spectrometry
KW - Germany/epidemiology
KW - Arginine/analogs & derivatives/blood
KW - Biological Markers/blood
KW - Coronary Disease/blood/diagnosis/mortality
M3 - SCORING: Journal article
VL - 102
SP - 193
EP - 202
JO - CLIN RES CARDIOL
JF - CLIN RES CARDIOL
SN - 1861-0684
IS - 3
M1 - 3
ER -
